The rising purchasing power of the population is also one of the reasons why the Eastern European Life Science market has been experiencing double-digit growth rates within the last years. Western as well as large Eastern European pharma players and an ever growing number of private equity funds are looking at the remaining generics companies in Eastern Europe.

Our sector knowledge together with the indispensable know how of the local culture, relationships and industries provided by our subsidiaries in every major CEE capital enable us to provide our clients with everything that is needed to realize their M&A ambitions in Central and Eastern Europe.